| Liraglutide: effects beyond glycaemic control in diabetes treatment. | |
| | |
MedLine Citation:
|
PMID: 20887302 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: To review the non-glycaemic effects of liraglutide, including potential improvements in body weight, systolic blood pressure (SBP) and pancreatic beta-cell function. KEY FINDINGS: Liraglutide induced weight loss of around 2-3 kg compared with weight increases of 1-2 kg with active comparators such as insulin glargine, rosiglitazone and glimepiride. Exenatide demonstrated similar weight benefits to liraglutide, but the dipeptidyl peptidase-4 (DPP-4) inhibitors, sitagliptin, saxagliptin and vildagliptin, were weight neutral. Liraglutide was associated with decreases in SBP of 2-7 mmHg, whereas exenatide, vildagliptin and sitagliptin demonstrated SBP reductions of around 2-3 mmHg. Measures of pancreatic beta-cell function were improved with liraglutide vs. placebo, rosiglitazone and exenatide. However, DPP-4 inhibitors appear to have less effect on beta-cell function than glucagon-like peptide-1 (GLP-1) receptor agonists. CONCLUSIONS: In addition to glycaemic control, liraglutide and the other incretin-based therapies offer additional non-glycaemic benefits to varying degrees. The ability of GLP-1 receptor agonists to provide modest, but clinically relevant improvements in body weight and SBP, and to potentially benefit beta-cell function make them an exciting therapeutic option for individuals with diabetes. In contrast, DPP-4 inhibitors are weight neutral and may have lesser benefits on beta-cell function. |
| | |
Authors:
|
J B McGill |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: International journal of clinical practice. Supplement Volume: - ISSN: 1368-504X ISO Abbreviation: Int J Clin Pract Suppl Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-10-04 Completed Date: 2011-04-27 Revised Date: 2011-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9712380 Medline TA: Int J Clin Pract Suppl Country: England |
Other Details:
|
Languages: eng Pagination: 28-34 Citation Subset: IM |
Copyright Information:
|
© 2010 Blackwell Publishing Ltd. |
Affiliation:
|
Division of Endocrinology, Metabolism and Lipid Research, Washington University in St. Louis, St Louis, MO 63110, USA. jmcgill@dom.wustl.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Blood Pressure
/
drug effects Body Weight / drug effects Diabetes Mellitus, Type 2* / drug therapy, metabolism, physiopathology Dipeptidyl-Peptidase IV Inhibitors / pharmacokinetics*, therapeutic use Glucagon-Like Peptide 1 / analogs & derivatives*, pharmacokinetics, therapeutic use Humans Hypoglycemic Agents / pharmacokinetics*, therapeutic use Insulin / analogs & derivatives Insulin-Secreting Cells / drug effects, metabolism Therapeutic Equivalency |
| Chemical | |
Reg. No./Substance:
|
0/Dipeptidyl-Peptidase IV Inhibitors; 0/Hypoglycemic Agents; 0/liraglutide; 11061-68-0/Insulin; 89750-14-1/Glucagon-Like Peptide 1 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Glycaemic control with liraglutide: the phase 3 trial programme.
Next Document: Clinical experience with liraglutide.